Vandetanib Drives Growth Arrest and Promotes Sensitivity to Imatinib in Hematologic Malignancies by Targeting Ephrin Type-B Receptor 4
2021
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI